RSS

regenerative medicine

The International Society for Cellular Therapy (ISCT) has stated its support of the US Food and Drug Administration’s (FDA’s) new comprehensive Regenerative Medicine Policy Framework. more

News

The CGT Catapult has signed a Memorandum of Understanding (MoU) with the FIRM in Japan, demonstrating a shared ambition to accelerate research and commercialisation of regenerative medicine. more

News

The Sartorius and Science Prize for Regenerative Medicine & Cell Therapy is focused towards scientists advancing research within the relevant fields, with the winner receiving $25,000 in prize money and being published in Science magazine more

News

Regenerative medicine is redefining medical technology synergies by combining stem cell technology with tissue engineering. more

News

Avita Medical, a regenerative medicine company specialising in new treatments for wounds and skin defects, has announced the launch of ReGenerCell for chronic wounds and ReNovaCell for repigmentation more

News

Orla Protein Technologies has developed an efficient means of determining the optimum protein surface required for different cell culture applications and research tasks. more

Technology

CiMaas, a developer of cellular immunotherapy for cancer, and PharmaCell, a contract manufacturer for cellular therapies and regenerative medicine in Europe, are collaborating in the clinical development of CiMaas’ products. more

News

A new range of human exosomes has been launched by AMSBIO for regenerative medicines research. Derived from placental and adipose stem cells, they are ideally suited for wound healing, stem cell differentiation and tissue regeneration applications. more

Technology

Cell therapies developer Plasticell has recruited Dr. Aaron Chuang chief scientific officer (CSO). Dr. Chuang takes on responsibility for preclinical therapeutic programmes and scientific oversight of collaborations and alliances, as well as external more

News

The immense potential of these medicines in repairing or regenerating diseased organs is the major reason for intensive focus on research and development in this field. more

Frost & Sullivan's Global Regenerative Medicine Market finds approval rates and clinical activity buzz point to regenerative medicine being attractive for investors. more

News